Important: Models were tasked with extracting evidence from documents. Some outputs may be low quality and should be scored accordingly.
Your task: Compare the model-generated prediction (right panel) against the ground truth criteria (left panel).
Evaluation scale (0-4):
Consider both content accuracy and completeness. Some predictions may be technically "correct" but incomplete or out of order.
INCLUSION CRITERIA 1. Documentation of relapsed or refractory CLLRequiring treatment per modified International Workshop on CLL (IWCLL) 2008 criteria; adults without radiographically measureable disease (defined as ≥ 1 lesion > 1.5 cm in diameter as assessed by computed tomography (CT) or magnetic resonance imaging (MRI)) must have bone marrow evaluation at screening 2. Adequate hematologic function: platelet count ≥ 50 × 10^9/L, neutrophil count ≥ 1 × 10^9/L, hemoglobin ≥ 8 g/dL unless lower values are directly attributable to documented bone marrow burden of CLLCreatinine clearance (CrCl) ≥ 50 mL/min 3. Total bilirubin ≤ 1.5× institutional upper limit of normal (ULN) unless attributed to Gilbert's syndrome and aspartate transaminase (AST)/alanine transaminase (ALT) ≤ 2.5×ULNEastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2 4. Absence of active human immunodeficiency virus (HIV), hepatitis B virus (HBV) infection, and hepatitis C virus (HCV) infection 5. Satisfies the following criteria:For females of childbearing potential, willingness to abstain from sexual intercourse or use a protocol-specified method of contraception as described in the study protocol 6. Males of reproductive potential who engage in sexual intercourse must agree to use protocol-specified method(s) of contraception as described in the study protocol 7. Able to comply with study procedures and restrictions EXCLUSION CRITERIA 1. Known transformation of CLL (ie, Richter's transformation, prolymphocytic leukemia)Known central nervous system (CNS) involvementProgression on treatment with any inhibitor of Bruton's tyrosine kinase (BTK), spleen tyrosine kinase (SYK), phosphatidylinositol 3-kinase (PI3K), B-cell lymphoma 2 (BCL-2), or obinutuzumab. 2. The treatment and disease response history of participants with prior treatment with agents in these classes should be reviewed by the sponsor or the German CLL Study Group office prior to enrollment to clarify sensitivity to these treatmentsAny treatment for CLL other than corticosteroids for symptomatic management within 28 days of the start of study treatmentParticipation on a concurrent therapeutic clinical trial unless all treatment is complete with only ongoing surveillanceDiagnosis of or concern for progressive multifocal leukoencephalopathyHistory of myelodysplastic syndrome or another malignancy other than CLL, except for the following: any malignancy that has been in complete remission for 3 years, adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for ≥1 year prior to start of study therapyActive infection requiring systemic therapyPregnant or nursing women (a negative pregnancy test is required for all women of childbearing potential within 7 days before start of treatment and monthly during therapy)Active autoimmune disease or the need for higher than prednisone 10 mg daily unless for management of CLL symptomsHistory of stroke or intracranial hemorrhage within 12 months of randomization; participants requiring therapeutic anticoagulation for any indication should be discussed with the German CLL Study Group (GCLLSG) cooperating physician and/or medical monitor prior to screeningAnticipated chronic use of strong CYP3A4/CYP2C9 inducers, moderate CYP2C9 inducers, or strong P-gp inducers while on study; use within 2 weeks of first dose of study treatment should be avoidedRequirement for proton pump inhibitor (PPI) therapyDemonstration of corrected QT (QTc) interval > 450 milliseconds or requirement for ongoing treatment with concomitant medications that prolong the QT intervalNote: Other protocol defined Inclusion/ EXCLUSION CRITERIA 1. may apply.
Based on the information provided, here is the revised eligibility criteria for version 28: Version Context: This task is for the transition from ClinicalTrials.gov version 27 to version 28. The evidence may use different labels (e.g. "Amendment 1", "Version 2.0"), but we'll assume the intent behind the changes is to make the eligibility criteria clearer and more precise. New Eligibility Criteria: 1. Number of Subjects: INCLUSION CRITERIA 1. Documentation of relapsed or refractory CLL 2. Must have an indication for treatment per modified IWCLL 2008 criteria 3. Must have bone marrow evaluation at screening 4. Adequate hematologic function as indicated by a platelet count ≥50 x 10^9/L, a neutrophil count ≥ 1 x 10^9/L and a hemoglobin ≥8g/dL unless lower values are directly attributable to documented bone marrow burden of CLL 5. Adequate renal function as indicated by a CrCl ≥50 mL/min calculated by the modified Cockroft-Gault formula or from a 24h urine collection 6. Adequate liver function as indicated by total bilirubin ≤1.5x institutional upper limit of normal (ULN) 7. Male or female ≥ 18 years of age 8. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2 9. EXCLUSION CRITERIA 1. Known Transformation of CLL (ie, Richter’s transformation, prolymphocytic leukemia) 2. Known CNS involvement 3. Progression on treatment with any inhibitor of BTK, SYK, PI3K, BCL-2, or obinutuzumab 4. Any treatment for CLL other than corticosteroids for symptomatic management within 28 days of the start of study treatment 5. Participation in a concurrent therapeutic clinical trial unless all treatment is complete with only ongoing surveillance 6. Diagnosis of or concern for progressive multifocal leukoencephalopathy 7. History of myelodysplastic syndrome or another malignancy other than CLL, except for the following: 8. Any malignancy that has been in complete remission for 3 years, adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for ≥1 year prior to start of study therapy. 9. Active infection requiring systemic therapy 10. Pregnant or nursing women (a negative pregnancy test is required for all women of childbearing potential within 7 days before start of treatment and monthly during therapy) 11. Involvement of Participants: 12. All subjects must be willing to abstain from sexual intercourse or use a protocol-specified method of contraception as described in the study protocol 13. Male subjects must agree to use protocol-specified method(s) of contraception as described in the study protocol 14. Female subjects must agree to use protocol-specified method(s) of contraception as described in the study protocol 15. This revision aims to clearly delineate the eligibility criteria for the study, making it easier for researchers to understand what subjects are eligible to participate in.